Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 7/20 | 0.39 |
| ▸ | CCR4 | P51679 | 1/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.37 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.37 |
| ▸ | TNIK | Q9UKE5 | 1/20 | 0.36 |
| ▸ | SUV39H2 | Q9H5I1 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.35 |
| ▸ | HTR3B | O95264 | 1/20 | 0.35 |
| ▸ | HTR3A | P46098 | 1/20 | 0.35 |
| ▸ | HTR3D | Q70Z44 | 1/20 | 0.35 |
| ▸ | HTR3C | Q8WXA8 | 1/20 | 0.35 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.34 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.34 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.34 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30741321 | 1.00 | EGFR (0.39) | EGFRCCR4KCNH2SCN5ATNIK | |
| SCHEMBL22942155 | 0.92 | ALK (0.40) | EGFRCCR4KCNH2SUV39H2ALK | |
| SCHEMBL22943290 | 0.92 | ALK (0.40) | EGFRCCR4KCNH2SUV39H2ALK | |
| SCHEMBL28087914 | 0.89 | CCR4 (0.40) | EGFRCCR4KCNH2SCN5ATNIK | |
| SCHEMBL30626536 | 0.87 | EGFR (0.43) | EGFR | |
| SCHEMBL20367139 | 0.85 | ALK (0.38) | EGFRCCR4KCNH2SCN5AMEN1 | |
| SCHEMBL22951258 | 0.85 | POLB (0.46) | EGFRCCR4KCNH2SCN5ATNIK | |
| SCHEMBL20367094 | 0.85 | TNIK (0.43) | EGFRCCR4KCNH2SCN5ATNIK | |
| SCHEMBL19174934 | 0.85 | GAA (0.45) | EGFRCCR4TNIKSUV39H2HTR3E | |
| SCHEMBL18843617 | 0.84 | ALK (0.43) | EGFRKCNH2SCN5AALK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230322822-A1 | ARYL PHOSPHOROUS OXIDE COMPOUNDS AND USE THEREOF | CHENGDU DI'AO JIUHONG PHARMACEUTICAL FACTORY (CN) | 2023-10-12 | — | — | US | disclosed |
| US-20230322822-A1 | ARYL PHOSPHOROUS OXIDE COMPOUNDS AND USE THEREOF | CHENGDU DI'AO JIUHONG PHARMACEUTICAL FACTORY (CN) | 2023-10-12 | — | — | US | disclosed |
| US-20230310428-A1 | EGFR INHIBITOR AND PREPARATION METHOD AND USE THEREOF | Hongyun Biotech Co., Ltd. (CN) | 2023-10-05 | — | — | US | disclosed |
| US-20230310428-A1 | EGFR INHIBITOR AND PREPARATION METHOD AND USE THEREOF | Hongyun Biotech Co., Ltd. (CN) | 2023-10-05 | — | — | US | disclosed |
| EP-4177258-A1 | ARYLPHOSPHINE OXIDE COMPOUNDS AND USE THEREOF | Chengdu Di'Ao Jiuhong Pharmaceutical Factory (CN) | 2023-05-10 | — | — | EP | disclosed |
| EP-3656769-B1 | ARYL-PHOSPHORUS-OXYGEN COMPOUND AS EGFR KINASE INHIBITOR | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO LTD (CN) | 2023-01-25 | — | — | EP | disclosed |
| WO-2022002241-A1 | ARYLPHOSPHINE OXIDE COMPOUNDS AND USE THEREOF | 成都地奥九泓制药厂 | 2022-01-06 | — | — | WO | disclosed |
| WO-2021238827-A1 | EGFR INHIBITOR AND PREPARATION METHOD AND USE THEREOF | 南京红云生物科技有限公司 | 2021-12-02 | — | — | WO | disclosed |
| EP-3372594-B1 | PYRIMIDINE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF CANCER | HUMANWELL HEALTHCARE GROUP CO LTD (CN) | 2021-07-21 | — | — | EP | disclosed |
| EP-3372594-B1 | PYRIMIDINE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF CANCER | HUMANWELL HEALTHCARE GROUP CO LTD (CN) | 2021-07-21 | — | — | EP | disclosed |
| WO-2017076355-A1 | PYRIMIDINE DERIVATIVE AND USE THEREOF | 湖北生物医药产业技术研究院有限公司 | 2017-05-11 | — | — | WO | disclosed |
| EP-2601186-A2 | 4-(1H-INDOL-3-YL)-PYRIMIDINES AS ALK INHIBITORS | AstraZeneca AB (SE) | 2013-06-12 | — | — | EP | disclosed |
| US-8461170-B2 | Chemical compounds | ASTRAZENECA AB (SE) | 2013-06-11 | — | — | US | disclosed |
| US-8461170-B2 | Chemical compounds | ASTRAZENECA AB (SE) | 2013-06-11 | — | — | US | disclosed |
| US-8461170-B2 | Chemical compounds | ASTRAZENECA AB (SE) | 2013-06-11 | — | — | US | disclosed |
| WO-2012017239-A2 | CHEMICAL COMPOUNDS | ASTRAZENECA AB (SE) | 2012-02-09 | — | — | WO | disclosed |
| WO-2012017239-A2 | CHEMICAL COMPOUNDS | ASTRAZENECA AB (SE) | 2012-02-09 | — | — | WO | disclosed |
| US-20120028924-A1 | CHEMICAL COMPOUNDS | ASTRAZENECA AB (SE) | 2012-02-02 | — | — | US | disclosed |
| US-20120028924-A1 | CHEMICAL COMPOUNDS | ASTRAZENECA AB (SE) | 2012-02-02 | — | — | US | disclosed |
| US-20120028924-A1 | CHEMICAL COMPOUNDS | ASTRAZENECA AB (SE) | 2012-02-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120028924-A1 | CHEMICAL COMPOUNDS | ALK, BRAF, ABL1 | EGFR 40/4885CCR4 3176/4885KCNH2 891/4885 |
| US-20230310428-A1 | EGFR INHIBITOR AND PREPARATION METHOD AND USE THEREOF | EGFR, ERBB2, ERBB4 | EGFR 1/4885CCR4 3858/4885KCNH2 4636/4885 |
| US-20230322822-A1 | ARYL PHOSPHOROUS OXIDE COMPOUNDS AND USE THEREOF | ALK, EGFR, ROS1 | EGFR 2/4885CCR4 4040/4885KCNH2 2813/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.